ID   MY-M12
AC   CVCL_3035
SY   MY clone M12; MYM12
DR   CLO; CLO_0037185
DR   cancercelllines; CVCL_3035
DR   Cell_Model_Passport; SIDM01217
DR   Cosmic; 2131569
DR   Cosmic-CLP; 1330960
DR   DepMap; ACH-002276
DR   GDSC; 1330960
DR   GEO; GSM1670138
DR   JCRB; JCRB0158.1
DR   JCRB; NIHS0246.1
DR   LINCS_LDP; LCL-1002
DR   PharmacoDB; MYM12_974_2019
DR   PRIDE; PXD030304
DR   Wikidata; Q54907142
RX   PubMed=9790503;
RX   PubMed=27397505;
RX   PubMed=30894373;
RX   PubMed=35839778;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: COSMIC cell lines project.
CC   Population: Japanese.
CC   Microsatellite instability: Stable (MSS) (Sanger).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: DNA methylation analysis.
CC   Genome ancestry: African=0.94%; Native American=0.38%; East Asian, North=81.47%; East Asian, South=16.04%; South Asian=1.17%; European, North=0%; European, South=0% (PubMed=30894373).
CC   Discontinued: JCRB; NIHS0246.1; true.
CC   Derived from site: In situ; Bone marrow; UBERON=UBERON_0002371.
CC   Cell type: Mononuclear cell; CL=CL_0000842.
ST   Source(s): Cosmic-CLP=1330960; JCRB=JCRB0158.1
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 8
ST   D16S539: 9
ST   D5S818: 11,13
ST   D7S820: 10,13
ST   TH01: 9
ST   TPOX: 8,11
ST   vWA: 17,18
DI   NCIt; C4673; Acute biphenotypic leukemia
DI   ORDO; Orphanet_530995; Mixed phenotype acute leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_3034 ! MY
SX   Female
AG   52Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 30
//
RX   PubMed=9790503; DOI=10.1002/(SICI)1098-2264(199811)23:3<227::AID-GCC4>3.0.CO;2-3;
RA   Inokuchi K., Shinohara T., Futaki M., Hanawa H., Tanosaki S.,
RA   Yamaguchi H., Nomura T., Dan K.;
RT   "Establishment of a cell line with variant BCR/ABL breakpoint
RT   expressing P180BCR/ABL from late-appearing Philadelphia-positive acute
RT   biphenotypic leukemia.";
RL   Genes Chromosomes Cancer 23:227-238(1998).
//
RX   PubMed=27397505; DOI=10.1016/j.cell.2016.06.017; PMCID=PMC4967469;
RA   Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P.,
RA   Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H.,
RA   Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H.,
RA   Deng X.-M., Egan R.K., Liu Q.-S., Mironenko T., Mitropoulos X.,
RA   Richardson L., Wang J.-H., Zhang T.-H., Moran S., Sayols S.,
RA   Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P.,
RA   Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H.,
RA   Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.;
RT   "A landscape of pharmacogenomic interactions in cancer.";
RL   Cell 166:740-754(2016).
//
RX   PubMed=30894373; DOI=10.1158/0008-5472.CAN-18-2747; PMCID=PMC6445675;
RA   Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.;
RT   "An interactive resource to probe genetic diversity and estimated
RT   ancestry in cancer cell lines.";
RL   Cancer Res. 79:1263-1273(2019).
//
RX   PubMed=35839778; DOI=10.1016/j.ccell.2022.06.010; PMCID=PMC9387775;
RA   Goncalves E., Poulos R.C., Cai Z.-X., Barthorpe S., Manda S.S., Lucas N.,
RA   Beck A., Bucio-Noble D., Dausmann M., Hall C., Hecker M., Koh J.,
RA   Lightfoot H., Mahboob S., Mali I., Morris J., Richardson L.,
RA   Seneviratne A.J., Shepherd R., Sykes E., Thomas F., Valentini S.,
RA   Williams S.G., Wu Y.-X., Xavier D., MacKenzie K.L., Hains P.G., Tully B.,
RA   Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.;
RT   "Pan-cancer proteomic map of 949 human cell lines.";
RL   Cancer Cell 40:835-849.e8(2022).
//